Eptifibatide-induced acute profound thrombocytopenia presenting as refractory hypotension
- 30 December 2002
- journal article
- case report
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 58 (1) , 76-79
- https://doi.org/10.1002/ccd.10392
Abstract
A 61‐year‐old woman presented with acute coronary syndrome and was given heparin and eptifibatide in conjunction with coronary angioplasty. Shortly thereafter she became profoundly thrombocytopenic (platelets 2.0 × 109/L) and developed severe refractory hypotension. Heparin‐induced antibodies were not detected, but the patient developed strong eptifibatide‐dependent antibodies specific for platelets that appear to explain both the thrombocytopenia and the hypotensive episode. Cathet Cardiovasc Intervent 2003;58:76–79.Keywords
This publication has 8 references indexed in Scilit:
- Evidence that thrombocytopenia observed in humans treated with orally bioavailable glycoprotein IIb/IIIa antagonists is immune mediatedBlood, 2002
- Severe thrombocytopenia possibly related to readministration of eptifibatideCatheterization and Cardiovascular Interventions, 2001
- Association of eptifibatide and acute profound thrombocytopeniaThe American Journal of Cardiology, 2001
- Thrombocytopenia complicating treatment with intravenous glycoprotein IIb/IIIa receptor inhibitors: A pooled analysisAmerican Heart Journal, 2000
- Understanding thrombocytopenia and antigenicity with glycoprotein IIb-IIIa inhibitorsAmerican Heart Journal, 1999
- Platelet activation as a potential mechanism of GP IIb/IIIa inhibitor-induced thrombocytopeniaThe American Journal of Cardiology, 1999
- Concurrence of anaphylaxis and acute heparin-induced thrombocytopenia in a patient with heparin-induced antibodiesJournal of Vascular Surgery, 1998
- Antibodies in sulfonamide-induced immune thrombocytopenia recognize calcium-dependent epitopes on the glycoprotein IIb/IIIa complexBlood, 1994